You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial

 

Online download statistics by month:

Online download statistics by month: January 2020 to September 2024

AbstractFullPdf
Jan 2020020
Feb 2020010
Mar 2020010
Apr 2020013
May 2020010
Jun 20200131
Jul 2020051
Aug 2020040
Sep 2020061
Oct 2020010
Nov 2020040
Dec 2020020
Jan 2021041
Feb 2021011
Mar 2021020
Apr 2021020
May 2021040
Jun 2021011
Jul 2021020
Aug 2021001
Sep 2021031
Oct 2021032
Nov 2021083
Dec 2021070
Jan 2022051
Feb 2022094
Mar 2022031
Apr 2022010
May 2022072
Jun 2022023
Jul 2022020
Aug 2022041
Sep 2022052
Oct 2022020
Nov 2022061
Dec 2022080
Jan 2023010
Feb 2023020
Mar 2023020
Jun 2023011
Jul 2023011
Aug 2023020
Sep 2023030
Oct 2023041
Nov 20230103
Dec 20230190
Jan 202402012
Feb 2024071
Mar 20240440
Apr 2024038
May 2024063
Jun 2024020
Jul 2024031
Aug 2024042
Sep 2024072
Total0233106